FDA Grants Priority Review to Genetech Breast Cancer Drug
On Tuesday, San Francisco-based Genentech announced that FDA will give its experimental breast cancer treatment pertuzumab a priority review. Genetech, a unit of Roche, said the agency will make a decision about the drug by June 8.
- "FDA Commits To Quick Review of New Genentech Breast Cancer Drug" (Leuty, San Francisco Business Times, 2/7).